Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination with Nivolumab/Ipilimumab for Patients with Metastatic Renal Cell Carcinoma

Renal Cancer
Sumanta Pal, MD
City of Hope Comprehensive Cancer Center


Metastatic renal cell carcinoma (mRCC) is difficult to treat, even with the encouraging combination of nivolumab and ipilimumab immunotherapy drugs. Only 42% of patients respond to this therapy, and recent studies suggest an imbalance in patient’s gut microbiome may play a role in this poor response. Dr. Pal and his team are testing adding a probiotic, CBM588, to the standard combination immunotherapy treatment in hopes that this probiotic helps to balance the gut microbiome and increase the effectiveness of the immunotherapy treatment for patients with mRCC.